Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
SLNO Soleno Therapeutics
- 49.1700
- -2.1600-4.21%
Close Feb 14 16:00 ET
- 49.1700
- 0.00000.00%
Post 16:52 ET
2.12BMarket Cap-17.62P/E (TTM)
52.4600High48.2850Low525.71KVolume51.5400Open51.3300Pre Close26.25MTurnover1.95%Turnover RatioLossP/E (Static)43.12MShares60.920052wk High8.01P/B1.33BFloat Cap36.610052wk Low--Dividend TTM26.96MShs Float742.5000Historical High--Div YieldTTM8.13%Amplitude0.8500Historical Low49.9270Avg Price1Lot Size
About Soleno Therapeutics Company
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Company Profile
SymbolSLNO
Company NameSoleno Therapeutics
Listing DateNov 13, 2014
Founded1999
CEODr. Anish Bhatnagar, M.D.
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address100 Marine Parkway,Suite 400
CityRedwood City
ProvinceCalifornia
CountryUnited States of America
Zip Code94065
Phone1-650-213-8444
Websitehttp://www.soleno.life
Company Executives
- Name
- Position
- Salary
- Dr. Anish Bhatnagar, M.D.
- President, Chief Executive Officer, Chief Operating Officer and Director
- 4.12M
- James H. Mackaness
- Chief Financial Officer and Principal Accounting Officer
- 1.21M
- Meredith S. Manning
- Chief Commercial Officer
- --
- Patricia C. Hirano
- Senior Vice President, Regulatory Affairs
- 1.03M
- Kristen Yen
- Senior Vice President, Clinical Operations
- --
- Dr. Michael Huang, M.D.
- Senior Vice President, Clinical Development
- --
- Dawn Carter Bir
- Director
- --
- Dr. Andrew Sinclair, PhD
- Independent Director
- 51.87K
- William G. Harris
- Independent Director
- 111.87K
- Dr. Birgitte Volck, M.D.,PhD
- Independent Director
- 102.87K
- Matthew Pauls, J.D.,M.B.A.
- Lead Independent Director
- 70.53K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.